Compare PERI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PERI | ADCT |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | Israel | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.4M | 445.2M |
| IPO Year | 2005 | 2019 |
| Metric | PERI | ADCT |
|---|---|---|
| Price | $10.46 | $3.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $14.50 | $7.75 |
| AVG Volume (30 Days) | 232.3K | ★ 1.2M |
| Earning Date | 05-20-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | $9.98 | N/A |
| Revenue Next Year | $2.48 | $66.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $8.07 | $1.69 |
| 52 Week High | $11.44 | $4.98 |
| Indicator | PERI | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 35.18 |
| Support Level | $9.37 | $3.40 |
| Resistance Level | $10.54 | $3.59 |
| Average True Range (ATR) | 0.33 | 0.22 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 33.47 | 12.34 |
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).